Alzheimer’s testing
Find out what’s behind memory changes
If you or someone close to you has noticed changes in memory or thinking, the first step is finding out why. Dr. Hall meets with you by video, arranges testing near home when it is needed, and explains the results himself.
See if this visit is right for you →About 2–3 minutes · No cost to submit · Dr. Hall reviews every request
How testing works
From symptoms to a clearer answer.
The testing is chosen to answer the clinical question, not as a one-size-fits-all panel.
Start with the clinical picture
Review memory and thinking changes, daily function, medical history, medications, and prior testing.
Look for biological evidence
When appropriate, Alzheimer’s blood testing, MRI, or other testing is completed near home.
Put the results together
Dr. Hall reviews the results in context and explains whether they support Alzheimer’s or point toward another next step.
Blood-based testing
About Alzheimer’s blood tests
Newer blood tests can show signs of Alzheimer’s with good accuracy. They’re one important piece of the picture. Dr. Hall reads the result alongside your symptoms, history, and other testing; a blood test alone doesn’t make the diagnosis. If a result is unclear, an amyloid PET scan is sometimes the next step.
Already have a result? If you’ve had an Alzheimer’s blood test through another doctor or on your own, Dr. Hall can review it as part of your evaluation and talk through what it means.
Why timing matters
Finding out early keeps more options open.
The newer Alzheimer’s treatments are for the early stages. Even when treatment isn’t the right choice, knowing the cause can help you and your family plan.
Clinical history, cognitive testing, and assessment of daily functioning establish the clinical syndrome and stage. When that pattern is compatible with mild cognitive impairment or mild dementia, FDA-cleared blood biomarker tests, particularly p-tau217-based assays, can identify Alzheimer's-related amyloid pathology with high accuracy. Amyloid PET remains an option when blood-test results are intermediate or otherwise unclear.
Amyloid accumulation generally begins early in the disease process and precedes widespread cortical spread of tau. As tau pathology spreads, it tracks much more closely with neuronal injury, cognitive impairment, and disease progression than amyloid burden itself. The leading model is that amyloid facilitates this later propagation of tau — one reason identifying and treating amyloid-positive disease before tau pathology becomes extensive may matter.
Disease-modifying therapies are the first treatments shown in randomized trials to reduce brain amyloid and slow cognitive and functional decline in early Alzheimer's disease.
This practice is built around accurate clinical staging, biologically confirmed diagnosis, evidence-based treatment, and structured safety oversight throughout care.
Ready to take the first step?
A quick form tells us whether a visit makes sense. Dr. Hall reviews every request himself.
See if this visit is right for you →